Literature DB >> 16407517

Reform of drug regulation--beyond an independent drug-safety board.

Wayne A Ray1, C Michael Stein.   

Abstract

Keywords:  Health Care and Public Health

Mesh：

Year:  2006        PMID： 16407517     DOI： 10.1056/NEJMsb053432

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  26 in total

1.  Why trash don't pass? pharmaceutical licensing and safety performance of drugs.

Authors:  Tannista Banerjee; Arnab Nayak
Journal:  Eur J Health Econ       Date:  2016-01-18

2.  Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization.

Authors:  Johan C F van Luijn; Frank W J Gribnau; Hubert G M Leufkens
Journal:  Br J Clin Pharmacol       Date:  2006-12-07       Impact factor: 4.335

3.  Discussion point: should governments buy drug patents?

Authors:  Juan del Llano
Journal:  Eur J Health Econ       Date:  2007-06

Review 4.  Open-label extension studies: do they provide meaningful information on the safety of new drugs?

Authors:  Richard O Day; Kenneth M Williams
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 5.  How can we regulate medicines better?

Authors:  Silvio Garattini; Vittorio Bertele'
Journal:  BMJ       Date:  2007-10-20

Review 6.  Gap in publication of comparative information on new medicines.

Authors:  Johan C F van Luijn; Pieter Stolk; Frank W J Gribnau; Hubert G M Leufkens
Journal:  Br J Clin Pharmacol       Date:  2008-02-21       Impact factor: 4.335

7.  Preemption, tort reform, and pharmaceutical claims: Part two: Has the Food and Drug Administration shown it is solely responsible for the protection of patients? Can it do so? Will it do so?

Authors:  Russell G Thornton
Journal:  Proc (Bayl Univ Med Cent)       Date:  2008-01

8.  Direct to consumer advertising of drugs in Europe.

Authors:  Nicola Magrini; Maria Font
Journal:  BMJ       Date:  2007-09-15

9.  Adverse event detection in drug development: recommendations and obligations beyond phase 3.

Authors:  Jesse A Berlin; Susan C Glasser; Susan S Ellenberg
Journal:  Am J Public Health       Date:  2008-06-12       Impact factor: 9.308

10.  Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer.

Authors:  Dawn L Hershman; Donna L Buono; Jennifer Malin; Russell McBride; Wei Yann Tsai; Alfred I Neugut
Journal:  J Natl Cancer Inst       Date:  2009-11-10       Impact factor: 13.506
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.